OncRef
Skip to newsletter content
|
NSCLCOctober 2026
0:00 / 3:58
Non-Small Cell Lung Cancer — Monthly Compass
Oct 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in non-small cell lung cancer this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
non-small cell lung cancer updates
Key Highlights
Key Highlights
  • Important Clinical Trial Publications
    • Phase III SAFFRON demonstrated that TAGRISSO (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated NSCLC after progression on TAGRISSO.
    • Iovance released updated Phase 2 IOV-LUN-202 data in previously treated non-squamous mNSCLC and stated that Cohorts 1/2 support a planned 2027 supplemental BLA for lifileucel with enrollment for a biomarker-enriched, registrational-intent cohort beginning in November 2026.
  • Key Clinical Development Updates
    • AstraZeneca submitted a U.S. NDA for TAGRISSO plus savolitinib targeting MET overexpression or amplification after progression on an EGFR TKI, while Cullinan initiated an RTOR-enabled rolling NDA for zipalertinib plus platinum chemotherapy in first-line EGFR exon 20 insertion NSCLC with a separate monotherapy NDA under FDA review and a PDUFA date of February 27, 2027.
    • Summit Therapeutics confirmed FDA acceptance of its BLA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC post–EGFR TKI with a PDUFA goal action date of November 14, 2026, and closed AstraZeneca’s $2 billion equity investment to accelerate ivonescimab development across ongoing Phase 3 NSCLC programs.
  • Key Conference Updates
    • ESMO 2026 NSCLC programming highlighted ADC momentum across lines with late-breaking datasets for sacituzumab tirumotecan head-to-heads (OptiTROP-Lung06/04), sigvotatug vedotin versus docetaxel (LBA68), and the EGFR×HER3 bispecific ADC izalontamab brengitecan in post-osimertinib EGFR-mutant disease (PANKU-Lung01, LBA71), spanning first-line PD-L1–negative, pretreated non-squamous, and post–EGFR-TKI populations.
    • Bispecific PD-(L)1×VEGF backbones featured prominently with pumitamig (BNT327/BMS986545) showing ROSETTA Lung-107 signals in second-line mNSCLC with docetaxel and ABBV-1480 demonstrating Phase 1 activity (ORR 61.9% in first-line PD-L1–positive and 66.7% with docetaxel post-therapy) alongside expected class toxicities including grade ≥3 hypertension/proteinuria and cytopenias in combination.
  • Emerging Themes & Macro-Trends
    • ADCs are poised to displace docetaxel in second line and to address EGFR-TKI resistance, with PANKU-Lung01 potentially introducing a targeted option post-osimertinib and PERSEE potentially narrowing IO-monotherapy use in PD-L1–high first-line disease.
    • PD-(L)1×VEGF bispecifics are emerging as scalable combination backbones that could reshape labeling considerations for partners and reduce reliance on cytotoxic doublets.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • There are no press releases between 2026-10-01 and 2026-10-31 about non-small cell lung cancer.
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Trethera announced that the FDA granted Fast Track designation to TRE-515 in combination with KRAS G12C inhibitors for patients with G12C mutation–positive non-small cell lung cancer who have progressed after anti–PD-(L)1 therapy and platinum-based chemotherapy. The company highlighted the designation as it advances development of TRE-515 combination regimens in this post-ICI, post-platinum setting. ¹ (read more)
  • Cullinan Therapeutics initiated a New Drug Application submission under the FDA’s Real-Time Oncology Review program for zipalertinib (CLN-081/TAS6417) plus platinum-based chemotherapy in previously untreated, locally advanced or metastatic EGFR exon 20 insertion mutation NSCLC. The company expects to complete the RTOR-enabled rolling NDA by year-end 2026; a separate monotherapy NDA remains under FDA review with a PDUFA target date of February 27, 2027. ² (read more)
  • Summit Therapeutics reported closing of AstraZeneca’s $2 billion equity investment and reiterated that the FDA accepted Summit’s BLA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC post–EGFR TKI, assigning a PDUFA goal action date of November 14, 2026. Summit stated the funding will accelerate ivonescimab development across ongoing Phase 3 NSCLC programs. ³ (read more)
  • AstraZeneca reported positive Phase III SAFFRON results of TAGRISSO (osimertinib) plus savolitinib in MET-driven EGFR-mutated NSCLC after progression on TAGRISSO and said a U.S. NDA for the combination was submitted to the FDA. The filing seeks approval for patients with MET overexpression or amplification whose disease progressed on an EGFR TKI. ⁴ (read more)
  • Crescent Biopharma announced FDA clearance of its Investigational New Drug application for CR-002, a PD-L1–targeted topoisomerase inhibitor antibody-drug conjugate, for advanced solid tumors. The Phase 1/2 APOLLO trial will include non-small cell lung cancer and head and neck squamous cell carcinoma cohorts, with trial initiation on track for Q4 2026. ⁵ (read more)
  • Iovance Biotherapeutics released updated Phase 2 IOV-LUN-202 data in previously treated non-squamous mNSCLC and said Cohorts 1/2 support a planned supplemental BLA for lifileucel in 2027. The company noted ongoing FDA discussions and plans to begin enrollment in November 2026 for a biomarker-enriched, registrational-intent cohort. ⁶ (read more)
Conference
Major Conference Updates
Conference Information
  • European Society for Medical Oncology (ESMO) Congress 2026; Madrid, Spain; October 23–27, 2026. (read more)
  • Overall sentiment: NSCLC programming spotlighted rapid ADC diversification, emergence of PD-(L)1×VEGF bispecific backbones, and consolidation radiotherapy—signaling near-term competitive pressure in post-IO and post–EGFR-TKI settings. (read more)
  • Theme 1: ADCs move center stage across lines
    • Significance: Multiple late-breaking NSCLC datasets position ADCs to challenge docetaxel and to address EGFR-TKI resistance, creating new targeted paths where chemotherapy dominates today. (read more)
    • Mechanism insights / clinical impact: Portfolio breadth spans sacituzumab tirumotecan (sac-TMT) head-to-heads (OptiTROP-Lung06/04), sigvotatug vedotin (SV) vs docetaxel (LBA68), and the bispecific ADC izalontamab brengitecan (iza-bren; EGFR×HER3) in “PANKU-Lung01” EGFR-mutant disease after third‑generation EGFR TKI—supporting efficacy hypotheses in chemo-refractory and driver‑positive segments. (read more)
    • Patient populations affected: First‑line PD‑L1‑negative non‑squamous NSCLC (sac‑TMT + pembrolizumab), pretreated non‑squamous NSCLC (SV), and EGFR‑mutant NSCLC post‑osimertinib (iza‑bren). (read more)
  • Theme 2: PD-(L)1×VEGF bispecific immunomodulators as backbones
    • Significance: Bispecific IO‑angiogenesis agents aim to consolidate checkpoint and anti‑VEGF benefits into single backbones and enable scalable combinations, potentially reducing reliance on cytotoxic doublets. (read more)
    • Mechanism insights / clinical impact: Pumitamig (BNT327/BMS986545; PD‑L1×VEGF‑A) delivered the first data from ROSETTA Lung‑107 (2L mNSCLC + docetaxel), while AbbVie’s ABBV‑1480 (PD‑1×VEGF) showed Phase 1 activity signals (ORR 61.9% 1L PD‑L1+; 66.7% with docetaxel post‑therapy) with expected class AEs (grade ≥3 hypertension/proteinuria; cytopenias in combo). (read more)
    • Patient populations affected: 2L metastatic NSCLC after chemo‑IO (pumitamig + docetaxel) and frontline or previously treated NSCLC without actionable alterations (ABBV‑1480 ± docetaxel). (read more)
  • Theme 3: Consolidation radiotherapy for oligometastatic disease
    • Significance: The SARON randomized trial’s primary results bring rigorous evidence to a practice where local therapy is variably adopted, potentially standardizing RT consolidation algorithms. (read more)
    • Mechanism insights / clinical impact: By ablating residual macroscopic disease post‑systemic therapy, consolidation RT could enhance disease control and delay new‑line therapy triggers. (Inferred from trial intent/title.) (read more)
    • Patient populations affected: Synchronous oligometastatic NSCLC across histologies, with implications for centers capable of integrated systemic‑RT care pathways. (read more)
  • Theme 4: Re-optimizing first-line and resistance settings with combinations
    • Significance: Head‑to‑head intensification in PD‑L1‑high (PERSEE) and targeted add‑on strategies post‑EGFR‑TKI (SAFFRON) test whether rational combinations can curb early progression and intercept MET‑driven resistance. (read more)
    • Mechanism insights / clinical impact: PERSEE (pembrolizumab ± platinum chemo) may redefine 1L PD‑L1 ≥50% therapy; SAFFRON (osimertinib + savolitinib vs platinum–pemetrexed) operationalizes MET overexpression/amplification biology post‑osimertinib. (read more)
    • Patient populations affected: 1L PD‑L1‑high advanced NSCLC; EGFR‑mutant, MET‑OE/AMP NSCLC post‑osimertinib. (read more)
  • Significance
    • Expected clinical or translational readouts: LBA series for sac‑TMT (OptiTROP‑Lung06/04), SV (LBA68), pumitamig (LBA76), and iza‑bren (PANKU‑Lung01, LBA71) drive cross‑modality benchmarks. (read more)
    • Regulatory or policy implications: Positive Phase 3 outcomes could catalyze 2027 submissions for post‑docetaxel and post‑EGFR‑TKI ADC indications; bispecific IO‑VEGF backbones may reshape labeling discussions around combination partners. (read more)
    • Potential shifts in standard of care: ADCs could displace docetaxel in 2L; successful PANKU‑Lung01 would introduce a targeted option after osimertinib; PERSEE outcomes may narrow IO‑monotherapy use in PD‑L1‑high disease. (read more)
    • Strategic implications: Invest in ADC companion diagnostics/biomarker ops; prioritize co‑development with PD‑(L)1×VEGF backbones; expand RT‑systemic trial networks for oligometastatic segments. (read more)
Publications Related to Approved Drugs
Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis. A pooled analysis of the CheckMate 227 and CheckMate 9LA studies demonstrates significant long-term survival benefits for first-line nivolumab plus ipilimumab, with or without chemotherapy, in Japanese patients with metastatic NSCLC and low PD-L1 expression (<1%). The combination achieved a 5-year overall survival rate of 38% versus 16% for chemotherapy alone, reinforcing its value as a standard-of-care option in this difficult-to-treat patient subgroup. (, )
Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT). In a post hoc analysis of the POSEIDON trial, a machine learning model successfully identified genetic signatures in patients with nonsquamous metastatic NSCLC who derive greater overall survival benefit from the addition of tremelimumab to durvalumab and chemotherapy. This approach, which identified mutations in KRAS and STK11 as key predictive factors, represents a significant step toward personalizing immunotherapy-chemotherapy regimens and enhancing treatment precision. ()
A Max 0-1 Weighted Log-Rank Test for Time-to-Event Data With Random Delayed Treatment Effect. This statistical research introduces a novel weighted log-rank test to more accurately assess immunotherapies that exhibit a delayed treatment effect, a common challenge in oncology trials. By applying this new method to data from a non-small-cell lung cancer trial, the authors demonstrate its potential to provide a more powerful and sensitive tool for designing and interpreting future clinical studies. ()
New Publications Related to Drugs in Clinical Trial Development
Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol. This article outlines the protocol for a phase II trial investigating whether adding narlumosbart (a RANKL inhibitor) and SBRT to first-line chemoimmunotherapy can improve efficacy in advanced driver gene-negative NSCLC with bone metastases. The primary endpoint is the objective response rate of non-irradiated lesions, based on the hypothesis that this combination can synergistically modulate the immunosuppressive tumor microenvironment. ()
Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD. The combination of osimertinib plus gefitinib demonstrated only modest clinical benefit (26% ORR, 5.1 months median PFS) in patients with EGFR-mutated advanced NSCLC who developed a C797X resistance mutation after first-line osimertinib. The risk-benefit profile does not support further evaluation of this regimen in this specific patient population. ()
Perioperative Pembrolizumab in Japanese Participants With Early-Stage NSCLC: Subgroup Analysis From KEYNOTE-671. A subgroup analysis of the KEYNOTE-671 study showed that perioperative pembrolizumab plus neoadjuvant chemotherapy improved efficacy outcomes, including event-free survival, compared to neoadjuvant chemotherapy alone in Japanese patients with early-stage NSCLC. The safety profile was manageable and consistent with the global study, supporting this regimen's use in this population. ()
Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. The first-in-class EGFR-HER3 bispecific ADC, izalontamab brengitecan (iza-bren), demonstrated encouraging antitumor activity in relapsed extensive-stage SCLC, with a notable 72.7% ORR in the second-line setting. These promising results, coupled with a manageable safety profile, support its ongoing evaluation in a phase III trial. ()
Biomarkers of nivolumab benefit in resectable non-small cell lung cancer. In the CheckMate 77T study, pre-surgical clearance of circulating tumor DNA (ctDNA) and achieving a pathologic complete response (pCR) were identified as key predictors of prolonged event-free survival (EFS) with perioperative nivolumab in resectable NSCLC. These findings highlight the potential of ctDNA as a predictive biomarker for outcomes and risk stratification in this patient population. ()
ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab. This prospective study found that detectable circulating tumor DNA (ctDNA) during and after consolidation durvalumab treatment was strongly associated with a higher risk of progression and shorter progression-free survival in patients with unresectable stage III NSCLC. Serial ctDNA-based minimal residual disease (MRD) assessment could identify high-risk patients who may benefit from intensified treatment strategies. ()
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial. The SWOG/NRG S1914 phase 3 trial found that adding neoadjuvant, concurrent, and adjuvant atezolizumab to stereotactic body radiation therapy (SBRT) did not improve overall survival in patients with high-risk, medically inoperable early-stage NSCLC. The combination therapy was also associated with a higher rate of grade 3 or higher adverse events compared to SBRT alone. ()
A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study. The OCEAN II study confirmed the clinical benefit of combining encorafenib and binimetinib in Chinese patients with BRAF V600E-mutated metastatic NSCLC, showing a confirmed objective response rate of 61% and a median progression-free survival of 13.8 months. The safety profile was consistent with previous findings, supporting this combination as a viable treatment option for this specific patient population. ()
Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study. The FRα-targeting ADC farletuzumab ecteribulin (FZEC) was evaluated in patients with pretreated solid tumors, with interstitial lung disease (ILD)/pneumonitis being a significant toxicity. The study found that fractionated dosing regimens appeared to reduce the risk of ILD/pneumonitis while showing preliminary antitumor activity, warranting further investigation of this strategy. ()
Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer. This study demonstrates that a liquid biopsy platform using cell-free ChIP-sequencing (cfChIP-seq) can noninvasively assess tumor burden and infer the major transcriptional subtypes (e.g., ASCL1, NEUROD1) of small-cell lung cancer directly from plasma. This technology provides a practical tool for real-time monitoring and could enable subtype-informed therapeutic strategies without the need for tissue biopsies. ()
At-home subcutaneous atezolizumab for non-small cell lung cancer: a prospective, single-arm phase II feasibility study. This small feasibility study demonstrated that at-home, nurse-administered subcutaneous atezolizumab for NSCLC patients is feasible, safe, and associated with high patient satisfaction. The at-home administration also resulted in a shorter measured administration time compared to in-clinic treatment, suggesting a potential to reduce patient burden. ()
Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lung Cancers: A Phase II Trial of Cabozantinib. The type II ROS1/MET TKI cabozantinib demonstrated clinical activity in a phase II trial for ROS1 fusion-positive NSCLC patients who had developed resistance to type I ROS1 inhibitors. The study achieved a 43% overall response rate, including responses in patients with multi-drug-resistant mutations like G2032R, highlighting the potential of type II inhibition to overcome acquired resistance. ()
A Max 0-1 Weighted Log-Rank Test for Time-to-Event Data With Random Delayed Treatment Effect. This paper proposes a new statistical testing method, a max 0-1 weighted log-rank test, designed to provide more optimal power for analyzing time-to-event data in clinical trials where the treatment effect is delayed, such as with immunotherapies. The usefulness of this method is demonstrated through simulations and an analysis of real-world data from a non-small-cell lung cancer clinical trial. ()
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study. This article details the protocol for the HYPERBOLIC phase 2 trial, the first prospective, biomarker-driven study designed to investigate whether adding short-course chemotherapy to first-line cemiplimab can reduce the rate of hyperprogressive disease (HPD) in NSCLC patients with PD-L1 ≥ 50%. The trial will use a high baseline level of circulating low-density neutrophils as a biomarker to identify patients at high risk for HPD. ()
Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study. Sofetabart mipitecan (Sofe-M), a novel FRα-targeting ADC, demonstrated a favorable safety profile and durable clinical activity in heavily pretreated high-grade ovarian cancer patients, irrespective of FRα expression or prior mirvetuximab soravtansine-gynx treatment. The recommended phase 3 dose was established as 3 mg/kg. ()
Nivolumab and cabozantinib in people with HIV and advanced solid tumors: a pilot trial and systematic review. A pilot trial of nivolumab plus cabozantinib in people living with HIV (PWH) and advanced solid tumors found the combination to have a manageable safety profile without compromising HIV virologic control. While efficacy could not be determined from the small cohort, durable disease stabilization was observed, supporting larger dedicated studies of this combination in PWH with cancer. ()
Rilvegostomig for Metastatic Non-Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study. The bispecific antibody rilvegostomig (anti-PD-1/TIGIT) showed a favorable tolerability profile but limited clinical efficacy in heavily pretreated, CPI-experienced patients with PD-L1-positive advanced NSCLC. While the objective response rate was low at 5.6%, the safety data support further evaluation in CPI-naïve patient populations. ()
Selpercatinib in Pediatric and Adolescent Patients With <i>RET</i>-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study. The LIBRETTO-121 study showed that selpercatinib, a selective RET inhibitor, was well-tolerated and demonstrated durable efficacy in pediatric and adolescent patients with RET-altered thyroid cancers. The objective response rate was 53% overall, with a 100% duration of response rate at 24 months, supporting the use of targeted RET inhibition in this younger patient population. ()
Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations. The mutant-selective EGFR TKI firmonertinib demonstrated significant clinical activity in the first-line treatment of patients with EGFR PACC-mutant NSCLC, a subgroup with limited options. The 240 mg dose achieved a 68% objective response rate and a median progression-free survival of 16.0 months, with good intracranial activity and a manageable safety profile. ()
Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib. The phase II LUCAS study showed that continuing the EGFR-TKI lazertinib in combination with platinum-pemetrexed chemotherapy after progression on prior lazertinib resulted in meaningful systemic and intracranial activity. The regimen achieved a median progression-free survival of 9.5 months with manageable toxicity, suggesting a potential benefit for this continuation strategy. ()
Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial. The first-in-class bispecific dual T cell agonist, invikafusp alfa, showed an acceptable safety profile and preliminary anti-tumor activity in patients with immune checkpoint blockade-resistant solid tumors, including non-small cell lung cancer. The study established a recommended phase 2 dose of 0.08 mg/kg based on safety, pharmacokinetic, and pharmacodynamic data. ()
Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study. The RELATIVITY-104 study did not meet its primary endpoint, as adding the LAG-3 inhibitor relatlimab to nivolumab plus chemotherapy did not significantly improve the objective response rate in an unselected first-line advanced NSCLC population. However, a positive trend in clinical benefit was observed in the subgroup of patients with PD-L1 ≥1% and nonsquamous histology, which warrants further investigation. ()
A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer. The c-Met targeting antibody-drug conjugate telisotuzumab adizutecan (Temab-A) in combination with bevacizumab demonstrated a favorable risk-benefit profile and clinically meaningful efficacy improvements compared to standard-of-care in patients with advanced colorectal cancer. The regimen showed higher objective response rates and improved survival outcomes, supporting its further evaluation in a phase 3 trial. ()
Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020). The PERSEE phase III trial demonstrated that first-line treatment with pembrolizumab plus platinum-based chemotherapy significantly prolonged progression-free survival compared to pembrolizumab monotherapy (16.1 vs. 6.9 months) in patients with advanced NSCLC and high PD-L1 expression (≥50%). This head-to-head comparison supports the combination strategy for improved outcomes in this patient population, despite a higher incidence of grade ≥3 adverse events. ()
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2. In the NeoCOAST-2 trial for resectable NSCLC, neoadjuvant treatment with datopotamab deruxtecan (Dato-DXd) plus durvalumab and chemotherapy resulted in the highest rates of ctDNA clearance and pathological complete response (pCR). The combined assessment of ctDNA clearance and pCR was strongly associated with improved event-free survival, suggesting its utility for risk stratification. ()
Divarasib as Compared with Sotorasib or Adagrasib in <i>KRAS</i> G12C-Mutated NSCLC. In the Krascendo 1 phase 3 trial, the next-generation KRAS G12C inhibitor divarasib led to significantly longer progression-free survival (9.8 vs. 5.7 months) and overall survival (17.7 vs. 12.0 months) compared to first-generation inhibitors (sotorasib or adagrasib). Divarasib also demonstrated a higher response rate and a more favorable safety profile, establishing it as a superior treatment option for previously treated KRAS G12C-mutated NSCLC. ()
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC. In the OptiTROP-Lung06 phase 3 trial, first-line treatment with sacituzumab tirumotecan plus pembrolizumab resulted in significantly longer progression-free survival (15.0 vs. 5.7 months) compared to standard chemotherapy plus pembrolizumab in patients with PD-L1-negative advanced nonsquamous NSCLC. This combination represents a promising new therapeutic option for this hard-to-treat patient population. ()
Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy. The SAFFRON phase 3 trial demonstrated that the combination of osimertinib and the MET-TKI savolitinib significantly prolonged both progression-free survival (HR 0.55) and overall survival (HR 0.68) compared to platinum-pemetrexed chemotherapy. This establishes a new standard of care for patients with EGFR-mutated, MET-overexpressed/amplified advanced NSCLC that has progressed on osimertinib. ()
ENTRÉE Lung: An Open-label Platform Study Investigating the Safety and Pharmacokinetics of Belrestotug Combinations in Advanced Non-Small Cell Lung Cancer. The ENTRÉE Lung study found that combining the anti-TIGIT antibody belrestotug with the anti-PD-1 dostarlimab (with or without the anti-CD96 nelistotug) was well-tolerated but showed no clinically meaningful activity in patients with advanced NSCLC who had progressed on prior anti-PD-(L)1 and platinum-based therapy. These results do not support further development of these specific combinations in this heavily pretreated population. ()
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China. In the HERON-Lung01 phase 3 trial, the HER3-directed ADC ruzaltatug rezetecan significantly prolonged progression-free survival compared to standard chemotherapy (median 8.3 vs. 5.4 months) in patients with EGFR-mutated advanced NSCLC resistant to EGFR-TKI therapy. The safety profile was manageable, positioning ruzaltatug rezetecan as a potential new treatment option in this setting. ()
Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China. The PANKU-Lung01 phase 3 trial showed that izalontamab brengitecan (iza-bren), a bispecific ADC targeting EGFR and HER3, significantly prolonged progression-free survival compared to platinum-based chemotherapy (11.1 vs. 5.7 months) in patients with EGFR-mutated NSCLC who progressed on third-generation EGFR TKIs. These findings establish iza-bren as a potential new standard of care in this setting, despite a higher frequency of grade 3 or worse adverse events. ()
Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial. The MDT-BRIDGE phase 2 study demonstrated the feasibility of a multidisciplinary team-guided approach using neoadjuvant durvalumab plus chemotherapy for resectable and borderline resectable NSCLC. This strategy enabled a high overall resection rate (74.6%) and allowed most patients to proceed to curative-intent treatment (surgery or CRT) followed by consolidation durvalumab, with a manageable safety profile. ()
TP53 Y220C hotspot mutation in clinically advanced ovarian carcinoma: Frequency and genomic features. This retrospective genomic analysis identified a 2.9% incidence of the potentially targetable TP53 Y220C mutation in clinically advanced ovarian carcinomas, making it one of the most frequent tumor types to harbor this specific alteration. This finding highlights a subset of patients who may be eligible for novel drugs that can restore wild-type TP53 function. ()
Cost-effectiveness analysis of sintilimab versus docetaxel as second-line therapy for squamous non-small cell lung Cancer in China. Based on data from the ORIENT-3 trial, a pharmacoeconomic analysis concluded that sintilimab is a cost-effective second-line therapy for advanced squamous NSCLC in China compared to docetaxel. Sintilimab provided an additional 0.32 quality-adjusted life years (QALYs) at an incremental cost-effectiveness ratio that falls below China's willingness-to-pay threshold. ()
A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial. A phase I trial combining an intratumoral CCL21-expressing dendritic cell vaccine with pembrolizumab in advanced NSCLC was well-tolerated and increased T cell infiltration into tumors. However, the combination did not result in objective responses, potentially due to an inability to fully overcome the immunosuppressive tumor microenvironment and a lack of persistent, tumor-specific T cell clones. ()
Sutetinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial. The irreversible EGFR-TKI sutetinib demonstrated clinically meaningful antitumor activity in a phase IIb trial for patients with advanced NSCLC harboring uncommon EGFR mutations (G719X, S768I, L861Q), achieving a confirmed objective response rate of 70.8% and a median progression-free survival of 13.7 months. With a manageable safety profile, sutetinib presents a potential new treatment option for this molecularly diverse patient population. ()
Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial. The AMAZE-lung phase 2 trial showed that the chemotherapy-sparing combination of amivantamab, lazertinib, and bevacizumab has promising anti-tumor activity in patients with EGFR-mutant NSCLC who progressed on a third-generation EGFR TKI. The regimen achieved a 12-week objective response rate of 33%, offering a potential alternative to chemotherapy-based combinations in this setting. ()
InDuRanS: neoadjuvant immunochemotherapy followed by surgery or definitive chemoradiotherapy and consolidation durvalumab in resectable and borderline resectable stage IIB-IIIA/B non-small-cell lung cancer. This article describes the protocol for the InDuRanS phase II trial, which is the first to prospectively randomize patients with resectable or borderline resectable stage IIB-IIIA/B NSCLC to either surgery or definitive chemoradiotherapy after receiving neoadjuvant immunochemotherapy. The study aims to define the optimal local treatment strategy in this setting, with a primary endpoint of 2-year event-free survival. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in non-small cell lung cancer updated from 2026-10-01 to 2026-10-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-------
Not Yet Recruiting441537235
Recruiting3540498273162
Available-------
Approved for Marketing-------
Active, Not Recruiting211421419-79
Completed-14-2-7
Total60598915555283
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Paclitaxel, Carboplatin, Cisplatin, Cetuximab, Oxaliplatin, Sasanlimab, PF-07934040, Fluorouracil, pemetrexed, Gemcitabine, Nab-paclitaxel, Bevacizumab, Leucovorin, Pembrolizumab NCT06447662 ACTIVE_NOT_RECRUITING A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene 2026-10-09
Mobocertinib NCT03807778 ACTIVE_NOT_RECRUITING A Phase 1/2 Study of the Oral EGFR/HER2 Inhibitor TAK-788 in Japanese Non-Small Cell Lung Cancer Patients 2026-10-28
Part A - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with AZD6094, Part C - AZD6094 monotherapy (Japan only), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part D - AZD9291 in combination with AZD6094, Part C - AZD9291 in combination with AZD6094 (Japan only), Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with intermittent selumetinib, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736 NCT02143466 ACTIVE_NOT_RECRUITING A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON). 2026-12-31
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Lazertinib/Pemetrexed/Carboplatin NCT05786430 COMPLETED Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib (LUCAS) 2026-08-23
Paclitaxel, Domvanalimab, Carboplatin, Zimberelimab, Pemetrexed, Pembrolizumab NCT04736173 COMPLETED Official Title: A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer 2026-09-17
Durvalumab NCT03999710 COMPLETED Durvalumab With Thoracic Radiation Therapy Without Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (DART) 2026-10-20
JDQ443 NCT05445843 ACTIVE_NOT_RECRUITING KontRASt-06: An Open-label Phase II Trial Evaluating the Activity and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. 2026-10-28
Paclitaxel, Carboplatin, Cisplatin, Tislelizumab, Nab paclitaxel, LBL-007, pemetrexed, BGB-15025, BGB-A445 NCT05635708 COMPLETED Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer 2026-10-29
Carboplatin, Paclitaxel, Tremelimumab, Durvalumab NCT03965468 ACTIVE_NOT_RECRUITING A Multicentre Single Arm Phase II Trial Assessing the Efficacy of Immunotherapy, Chemotherapy and Stereotactic Radiotherapy to Metastases Followed by Definitive Surgery or Radiotherapy to the Primary Tumour, in Patients With Synchronous Oligo-metastatic Non-small Cell Lung Cancer 2026-12
: Pembrolizumab NCT04032418 ACTIVE_NOT_RECRUITING Randomized Phase II Study of Pembrolizumab 200mg every12 Weeks Versus Every 3 Weeks in NSCLC With Clinical Benefit to Pembrolizumab Monotherapy: Multicenter International Study 2026-12-14
[No Drug Info] NCT06660407 ACTIVE_NOT_RECRUITING Grid Radiotherapy for Advanced Non-Small Cell Lung Cancer at the Time of Progression on Immune Checkpoint Inhibition 2027-01-10
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Paclitaxel, : Pembrolizumab IV, Carboplatin, Cisplatin, Pemetrexed, : Pembrolizumab SC, Nab-Paclitaxel NCT04956692 COMPLETED A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab, Administered With Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants With Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer 2026-08-24
Carboplatin, TAK-788, Cisplatin, Pemetrexed NCT04129502 COMPLETED A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations 2026-09-22
Ramucirumab, Osimertinib, Gefitinib, Erlotinib NCT02411448 ACTIVE_NOT_RECRUITING A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer 2026-12
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
No phase 4 trials completing within the next three months.
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.